Table 5. Adverse events seen during atezolizumab (ATZ) plus bevacizumab (BEV) in 82 patients with unre sectable hepatocellular carcinoma (HCC).
| Events | Number of Patients (%) | ||||
| Total | Grading: CTCAE version 4 | ||||
| 1 | 2 | 3 | 4 | ||
| Any adverse events | 77 (94) | 14 (17) | 41 (50) | 20 (24) | 2 ( 2) |
| Rash | 08 (10) | 05 (06) | 03 (04) | 0 | 0 |
| Diarrhea | 03 (04) | 02 (02) | 01 (01) | 0 | 0 |
| Colitis | 01 (01) | 0 | 01 (01) | 0 | 0 |
| decreased appetite and/or nausea | 21 (26) | 14 (17) | 04 (05) | 03 (04) | 0 |
| general fatigue | 17 (21) | 16 (20) | 0 | 01 (01) | 0 |
| Ascites | 11 (13) | 01 (01) | 10 (12) | 0 | 0 |
| Hypertension | 03 (04) | 0 | 02 (02) | 01 (01) | 0 |
| hepatic encephalopathy | 01 (01) | 0 | 01 (01) | 0 | 0 |
| Leukopenia | 10 (12) | 2 (2) | 7 (9) | 01 (01) | 0 |
| Anemia | 26 (32) | 14 (17) | 07 (09) | 05 (06) | 0 |
| Thrombocytopenia | 16 (20) | 11 (13) | 02 (02) | 03 (04) | 0 |
| increased serum total bilirubin | 22 (27) | 10 (12) | 08 (10) | 03 (04) | 01 (01) |
| elevated serum alanine aminotransferase | 27 (33) | 19 (23) | 07 (09) | 01 (01) | 0 |
| decreased serum albumin | 39 (48) | 06 (07) | 26 (32) | 07 (09) | 0 |
| increased serum creatinine | 19 (23) | 15 (18) | 03 (04) | 01 (01) | 0 |
| Hypothyroidism | 01 (01) | 0 | 01 (01) | 0 | 0 |
| Proteinuria | 64 (78) | 42 (51) | 16 (20) | 06 (07) | 0 |
| adrenal insufficiency | 01 (01) | 0 | 0 | 01 (01) | 0 |
| infusion reaction | 01 (01) | 0 | 0 | 0 | 01 (01) |
| GI bleeding | 3 (04) | 0 | 0 | 03 (04) | 0 |